Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US

Chief Financial Officer

Chief Research Officer and Co-Founder

President and Chief Operating Officer

Independent Director

Member of the Board of Directors

Aerie Pharmaceuticals has offices in Irvine, Bedminster Township, Durham and Dublin

Irvine, US (HQ)

2030 Main St

Dublin, IE

28 32 Pembroke Street

Durham, US

4301 Emperor Blvd

Bedminster Township, US

135 Us 206

USD

## Net income (FY, 2016) | (99.1 m) |

## EBIT (FY, 2016) | (96.9 m) |

## Market capitalization (21-Jul-2017) | 2 b |

## Cash (31-Dec-2016) | 197.9 m |

Aerie Pharmaceuticals's current market capitalization is $2 b.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## R&D expense | (52.4 m) | |||

## General and administrative expense | (44.5 m) | |||

## Operating expense total | (96.9 m) | |||

## EBIT | (96.9 m) | |||

## Pre tax profit | (98.9 m) | |||

## Income tax expense | (193 k) | |||

## Net Income | (31.1 m) | (48.1 m) | (74.4 m) | (99.1 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} |
---|---|---|---|---|---|---|---|---|

## R&D expense | (10.6 m) | (9.9 m) | (12.3 m) | (13.3 m) | (12.7 m) | |||

## General and administrative expense | (7.5 m) | (7.5 m) | (9.8 m) | (9.4 m) | (10.6 m) | |||

## Operating expense total | (18.1 m) | (17.4 m) | (22.1 m) | (22.7 m) | (23.3 m) | |||

## EBIT | (18.1 m) | (17.4 m) | (22.1 m) | (22.7 m) | (23.3 m) | |||

## Pre tax profit | (18.6 m) | (17.9 m) | (22.7 m) | (23.2 m) | (23.8 m) | |||

## Income tax expense | (152 k) | (72 k) | (46 k) | (47 k) | (39 k) | |||

## Net Income | (18.5 m) | (31.6 m) | (17.2 m) | (36 m) | (54 m) | (22.7 m) | (45.9 m) | (69.7 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 69.6 m | 85.6 m | 91.1 m | 197.9 m |

## Accounts Receivable | 399 m | |||

## Inventories | 618 k | 1.1 m | 1.9 m | 4 m |

## Current Assets | 70.3 m | 141 m | 138.4 m | 237.7 m |

## Total Assets | 70.5 m | 161.1 m | 159.1 m | 248.3 m |

## Accounts Payable | 3.5 m | 551 k | 551 k | 551 k |

## Current Liabilities | 3.5 m | 8.9 m | 17.1 m | 19.4 m |

## Total Liabilities | 142.9 m | |||

## Additional Paid-in Capital | 162 m | 171.3 m | 236.5 m | 422 m |

## Retained Earnings | (143.2 m) | (217.6 m) | (316.6 m) | |

## Total Equity | 67 m | 18.8 m | 105.3 m | |

## Financial Leverage | 1.1 x | 8.5 x | 2.4 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} |
---|---|---|---|---|---|---|---|---|

## Cash | 27.9 m | 148.9 m | 113.5 m | 100.9 m | 106.9 m | 74.3 m | 58.5 m | 211.9 m |

## Current Assets | 57.3 m | 171.7 m | 171 m | 159.9 m | 156.6 m | 120.7 m | 108.2 m | 256.5 m |

## Total Assets | 57.7 m | 173.3 m | 195.2 m | 176.3 m | 175.2 m | 139.2 m | 120.1 m | 265.9 m |

## Accounts Payable | 4.8 m | 7 m | 21.9 m | 17.7 m | 18 m | 15.5 m | 13.6 m | 13.5 m |

## Current Liabilities | 4.8 m | 7 m | 22.4 m | 18.3 m | 18.5 m | 16 m | 14.1 m | 14.1 m |

## Additional Paid-in Capital | 166.4 m | 168.8 m | 209.1 m | 213.1 m | 229.7 m | 240.2 m | 246.1 m | 415.6 m |

## Retained Earnings | (160.4 m) | (179.2 m) | (197.2 m) | (240.3 m) | (263.5 m) | (287.3 m) | ||

## Total Equity | 52.9 m | 42.2 m | 33.9 m | 32.5 m | 128.4 m | |||

## Financial Leverage | 1.1 x | 4.1 x | 5.2 x | 5.4 x | 2.1 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (31.1 m) | (48.1 m) | (74.4 m) | (99.1 m) |

## Depreciation and Amortization | 64 k | 73 k | 252 k | 970 k |

## Accounts Payable | 2 m | 551 k | ||

## Cash From Operating Activities | (16.4 m) | (33.7 m) | (55.7 m) | (79.8 m) |

## Cash From Investing Activities | (63 k) | (73.3 m) | 9.4 m | 18.1 m |

## Cash From Financing Activities | 83.2 m | 123 m | 51.8 m | 168.6 m |

## Interest Paid | 2.2 m | 2.2 m | ||

## Income Taxes Paid | 600 k | 1.8 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} |
---|---|---|---|---|---|---|---|---|

## Net Income | (18.5 m) | (31.6 m) | (17.2 m) | (36 m) | (54 m) | (22.7 m) | (45.9 m) | (69.7 m) |

## Depreciation and Amortization | 31 k | 50 k | 24 k | 60 k | 102 k | 223 k | 457 k | 702 k |

## Accounts Payable | 1.4 m | 2.3 m | (12 k) | (6 k) | 2.4 m | (6 k) | (6 k) | |

## Cash From Operating Activities | (12.9 m) | (22.4 m) | (13.3 m) | (29.6 m) | (41.5 m) | (19.4 m) | (39.8 m) | (61 m) |

## Cash From Investing Activities | (28.9 m) | (22.6 m) | 6.1 m | 9.3 m | 14.4 m | 2.4 m | 5.1 m | 14 m |

## Cash From Financing Activities | 74 k | 124.2 m | 35.1 m | 35.6 m | 48.5 m | 128 k | 2.2 m | 167.9 m |

## Interest Paid | 551 k | 1.1 m | 1.6 m | 551 k | 1.1 m | 1.6 m | ||

## Income Taxes Paid | 469 k | 600 k | 1.8 m | 1.8 m | 1.8 m |

Y, 2016 | |
---|---|

## Financial Leverage | 2.4 x |